Biogen

Pic:getty/andrewbrookes

Biogen releases long-term Aduhelm data

By Rachel Arthur

Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.

Pic:getty/alengo

Biogen backs late-stage bispecific antibody with $30m

By Rachel Arthur

Biogen has exercised its option to participate in the development and commercialization of mosunetuzumab, an investigational T-cell engaging biospecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic...

Pic:getty/andrewbrookes

Biogen halves price of Aduhelm in the US

By Rachel Arthur

As of January 1, 2022, Biogen will cut the price of its Alzheimer’s drug Aduhelm (aducanumab-avwa) in half: saying too many patients are not currently being offered the choice of the drug due to financial considerations.

© GettyImages/DNY59

FDA lead calls for independent inquiry into Biogen drug approval

By Jane Byrne

Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....

Pic:getty/CG6images

FDA approves Biogen’s Alzheimer's drug, Aduhelm

By Rachel Arthur

The US Food and Drug Administration (FDA) has approved Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s: making it the first new treatment approved for the disease since 2003.

(Image: Getty/Motortion)

UPDATED

Questions mount over Samsung accounting case

By Maggie Lynch

An executive at Samsung is issued an arrest warrant, as prosecutors in South Korea continue to look into the accounting case leading up the IPO of Samsung BioLogics.

(Image: Getty/Dragana991)

A troubled timeline of Alzheimer’s trials

By Ben Hargreaves

After Biogen’s setback in the space, the number of treatments that have not succeeded in making an impact on Alzheimer’s disease continues to grow.

(Image: Getty/pinkypills)

Nightstar acquired by Biogen for $800m

By Maggie Lynch

Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.

(Image: Getty/SonerCdem)

Sandoz bows out of US Rituxan biosimilar race

By Ben Hargreaves

After the business was asked by the US FDA to provide more data to secure an approval for its biosimilar, Sandoz decided not to pursue its regulatory filing any further.